Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

UK governments settle legal case with Reckitt Benckiser over Gaviscon

Gaviscon Liquid

The competition issues relating to Gaviscon supplies go back to 2010.

The health ministries of Scotland, Wales and Northern Ireland have reached a “full and final” settlement with Reckitt Benckiser over the company’s decision to withdraw its off-patent Gaviscon Original Liquid from prescription on the NHS to the advantage of its alternative product still under patent.

The patent for Gaviscon Original Liquid ended in 1997 and its withdrawal from the NHS prescription channel took place in 2005, ahead of publication of its generic name in prescribing systems. Any subsequent searches for “Gaviscon” would identify Gaviscon Advance Liquid — which is patent protected until 2016 — and not Gaviscon Original Liquid, for which alternatives can be prescribed.

In 2010, the Office of Fair Trading (OFT) fined Reckitt Benckiser £10.2m after it concluded the company abused its dominant market position. Civil claims for damages from the health authorities in England, Wales, Scotland and Northern Ireland ensued.

A spokesperson for the Scottish Government says that it cannot disclose the “sums” involved in the settlement because of the nature of the undisclosed agreement. The Department of Health in England reached a similar agreement in February 2014.

Reckitt Benckiser’s 2013 annual report notes that the company is involved in certain competition law-related proceedings with pharmaceutical companies and with several countries. The report says that the company has put aside £225m to deal with “competition matters”.

Reckitt Benckiser declined to comment on the Gaviscon market in the UK.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.11138558

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Disease Management

    Disease Management

    Disease Management covers the diseases commonly encountered in primary care by system, with common therapeutic issues. Includes case studies and self-assessment sections.

    £54.00Buy now
  • Developing Your Prescribing Skills

    Developing Your Prescribing Skills

    Developing Your Prescribing Skills uses case studies, mind maps and feedback from experienced prescribers. It supplies practical advice on the issues facing prescribers in all types of practice.

    £23.00Buy now
  • Workplace Drug Testing

    Workplace Drug Testing

    Explains drug testing regulatory frameworks and all aspects of drug analysis. Case studies of successful programmes are included.

    £81.00Buy now
  • Social and Cognitive Pharmacy

    Social and Cognitive Pharmacy

    Social and Cognitive Pharmacy is a practical handbook for learning and teaching sociology and psychology, and applying this to pharmacy practice.

    £33.00Buy now
  • Clinical Pharmacokinetics

    Clinical Pharmacokinetics

    A practical guide to the use of pharmacokinetic principles in clinical practice. Includes case studies with questions and answers.

    £33.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.